The article examines issues concerning Hepatitis C management in dialysis patients. The leading cause of chronic liver disease worldwide, infection with the hepatitis C virus (HCV) has an estimated prevalence of 3% in the world population. Information related to the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C workgroup is provided.